Robert (Bob) Ward is President and Chief Executive Officer of Radius. He is a global pharmaceutical industry leader managing all stages of drug development, commercialization, and strategic dealmaking and partnerships across multiple therapeutic areas. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of AstraZeneca (AZ), where he led search and evaluate activities in areas outside of AZ’s historical therapeutic focus, including orphan drugs and endocrinology. In addition, he served as Co-Chair of the Joint Development Committees in AZ’s drug development partnerships with Alcon and Galderma. After starting his career in the Molecular Biology discovery group at Genentech, Mr. Ward progressed through a series of management and executive roles with established biopharmaceutical companies including NPS Pharmaceuticals, Schering-Plough (Merck), and Bristol-Myers Squibb. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara; an M.S. in Management from the New Jersey Institute of Technology; and an M.A. in Immunology from The Johns Hopkins University School of Medicine.
Nick Harvey is Senior Vice President and Chief Financial Officer of Radius. He has more than 15 years of experience in building and financing life sciences and technology companies. Prior to joining Radius, he served for four years as Managing Director of Shiprock Capital, a venture capital firm, where he was responsible for deal-sourcing, negotiating and closing transactions, and developing strategic plans for portfolio companies. Before that, Mr. Harvey served as CFO of a number of venture-backed companies over a 10-year period, including Transfusion Technologies and Transcend Therapeutics. At Transfusion, he helped to close a major distribution agreement with Zimmer and oversaw the company's acquisition by Haemonetics. Mr. Harvey holds an undergraduate degree in Economics and a law degree with first-class honors from the Australian National University, and an MBA from the Harvard Business School.
Dr. Harris is Chief Medical Officer of Radius. He has over 25 years of experience in clinical research and development. Dr. Harris carries expertise in endocrinology, metabolism, diabetes, oncology, gastroenterology, cardiovascular disease, allergic and respiratory diseases. He has played a central role in the approval process and clinical development of 17 peptides, small molecules, and biological pharmaceutical drugs, including Natpara® (rhPTH 1-84) and has conducted or overseen hundreds of clinical trials in over 30 countries. Dr. Harris was the Senior Vice President of R&D and the Chief Medical Officer of NPS Pharmaceuticals, Therapeutic Head of Worldwide Medical Endocrine Care for Pfizer. Dr. Harris worked for nine years at Schering Plough, in a number of positions related to scientific and medical affairs, including Vice President of Global Health Research and Outcomes. During his tenure at Novartis he headed the clinical development of a major therapeutic peptide breakthrough therapy, octreotide (Sandostatin®), the first long-acting somatostatin analog approved worldwide for the treatment of malignant gastrointestinal endocrine tumors and growth hormone-producing tumors. Dr. Harris was an associate professor of medicine at the University of California, Los Angeles from 1992 to 1994 and has been an adjunct professor of medicine endocrinology at New York University since 2003. Dr. Harris received his medical degree from the Louis Pasteur Faculty of Medicine, University of Strasbourg, France, and his Ph.D. in endocrinology from Erasmus University, Rotterdam, The Netherlands. Dr. Harris is the founder and chairman of Sompharmaceuticals SA, a Swiss company focused on the discovery and development of new generation of somatostatin peptide analogues for the treatment of Growth Hormone producing brain tumors that cause acromegaly and malignant Neuroendocrine Tumors (NETs) including carcinoids. Dr. Harris earned his medical degree from the Louis Pasteur Faculty of Medicine, University of Strasbourg, France, and his Ph.D. in endocrinology from Erasmus University, Rotterdam, The Netherlands. Dr Harris has authored over 120 peer reviewed scientific papers.
Dr. Williams is Chief Development Officer of Radius. He is a pharmaceutical industry and drug development veteran with more than 30 years of experience leading new product development, regulatory affairs, lifecycle management and commercialization for both small biotechnology and large pharmaceutical companies. Prior to joining Radius, Dr. Williams was Vice President of Regulatory Affairs, Global Product and Clinical Development, and Program Management with The Medicines Company, where he led the successful NDA and MAA filings of the IV antihypertensive drug Cleviprex®. Earlier positions include Vice President of Regulatory Affairs, Regulatory Compliance and Program Management for NPS Pharmaceuticals, where he led the successful MAA filing of the osteoporosis drug Preotact™. He has also held various management positions in clinical and drug product development for Yamanouchi Pharma America, Theraport Biosciences, GlaxoSmithKline Consumer Healthcare, and Parke-Davis Pharmaceutical. Dr. Williams has a Ph.D. in Biopharmaceutics from Rutgers University and an MBA from Cornell University. Dr. Hattersley is Chief Scientific Officer of Radius. He has more than 20 years of experience in musculoskeletal research and is the author of numerous scientific publications related to bone biology and physiology. Prior to joining Radius, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals with responsibility for the discovery and development of novel small-molecule agents for the treatment of osteoporosis and other metabolic bone diseases. Dr. Hattersley also held positions at Genetics Institute/Wyeth Research investigating the application of the bone morphogenetic proteins in bone and connective tissue repair and regeneration. Dr. Hattersley received a PhD in Experimental Pathology from St. George's Hospital Medical School in London. Lauren Gallagher is Vice President of Finance at Radius. She has more than 10 years of accounting and finance experience. Prior to joining Radius, she served as Director of External Reporting at American Tower Corporation, a leading global owner, operator and developer of wireless and broadcast communications real estate, where she was responsible for building and leading the company’s reporting function and for a wide range of activities including financial statement preparation, SEC filings and technical accounting. Before that, Ms. Gallagher provided accounting and consulting services to clients in a variety of industries, including financial services, IT consulting, telecommunications, retail, manufacturing, and technology. Ms. Gallagher began her career as an auditor for KPMG, where she planned and administered audit engagements for several large public companies. Ms. Gallagher holds a B.S. in Accounting and a Master of Science in Accounting from the University of Massachusetts at Amherst. Ms. Gallagher is also a Certified Public Accountant. Geoff Swire is Vice President of Business Development & Strategy of Radius. He has more than 15 years of experience leading development and commercial teams to build successful biopharmaceutical businesses. Prior to joining Radius, he served as Vice President, Global Commercial Operations in Genzyme’s Transplant & Oncology business unit, where he was responsible for leading the global integration of three hematology brands from Bayer HealthCare in over 90 markets. Earlier at Genzyme, as head of program management for the Transplant business unit, he established and directed the search and evaluation team that brought in Mozobil through the acquisition of AnorMED and led development teams responsible for major NDA/MAA submissions. Before that, Mr. Swire led transformational initiatives for global pharmaceutical companies as a senior manager in Accenture’s Health & Life Sciences strategy consulting practice. Mr. Swire holds a B.A. from Dartmouth College and an M.P.P. concentrating on financial markets and analysis from Harvard University.